SB CellsTreatment Reduces IL-6 in Type 1 Diabetes Mellitus Patients
Abstract
Xiao Chen, Pei-Ju Chu, Monica Lui, Tina Zhang, Lee Chen, Wen Ying Lee, Puning Cheng, Jessica Ding, Tommy Flashman, and James Wang
Type 1 diabetes mellitus is an auto-immune disease that results in the destruction of insulin-producing β-islet cells of the pancreas. Current research has shown that IL-6, an inflammatory cytokine, is elevated in those with type 1 diabetes, and may be involved in disease progression. Despite advancements in type 1 diabetes research, the primary therapy for mediating glucose uptake in patients with type 1 diabetes remains to be daily injections of exogenous insulin or insulin-analogues. While these treatments are established methods for lowering blood glucose, daily injections can be burdensome for patients. In order to aid patients and ease the lifelong dependence on injections, alternative approaches to type 1 diabetes disease pathology must be investigated. In particular, stem cell research has shown promising results in reducing inflammation. This study aims to investigate the effects of StemBios stem cell therapy on reducing inflammatory markers and stabilizing blood glucose levels. In order to quantify the effects of the SBcells® (StemBios cells) treatment, glycated hemoglobin (HbA1c) and interleukin-6 (IL-6) levels were recorded before and after the treatment. The study patient’s HbA1c and IL-6 levels both decreased during the treatment and these findings suggest that the SB cells® treatment can ameliorate the inflammatory process and provide beneficial outcomes for type 1 diabetics.